---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-028281"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-13T23:51:05.887711+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics annual meeting results: all proposals approved

## Summary
- 19,500,381 shares present (≈60% of outstanding); quorum met.
- Elected Class III directors Palasis (16.4M for), Smith (16.3M for), Tobin (16.6M for).
- Ratified BDO USA as independent auditor for FY 2023 (9.5M for, 8K against).

## SEC filing metadata
- accession: 0000950170-23-028281
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/0000950170-23-028281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/lyra-20230613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-028281
- JSON: https://secwatch.observer/filing/0000950170-23-028281.json
- Plain text: https://secwatch.observer/filing/0000950170-23-028281.txt

## Key facts
- Shareholder Votes
  Lyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 9,471,462 8,427 20,492 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/0000950170-23-028281-index.htm
- Shareholder Votes
  Lyra Therapeutics, Inc. shareholders approved Election of three Class III Directors to serve until the Company’s 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2023-06-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Maria Palasis, Ph.D. 16,444,471 29,445 2,826,465 W. Bradford Smith 16,337,920 335,996 2,826,465 James R. Tobin 16,638.595 35,321 2,826,465
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/0000950170-23-028281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.